Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.
SARS-CoV-2
breakthrough infection
hematological diseases
immunocompromised patients
prophylaxis
tixagevimab-cilgavimab
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 Sep 2023
01 Sep 2023
Historique:
revised:
20
07
2023
received:
14
05
2023
accepted:
20
07
2023
medline:
2
9
2023
pubmed:
2
9
2023
entrez:
2
9
2023
Statut:
aheadofprint
Résumé
Managing SARS-CoV-2 infection in frail and immunosuppressed patients still represents an open challenge, but, starting from the phase 3 PROVENT study, prophylaxis with tixagevimab-cilgavimab has improved the approach in this category of patients, guaranteeing a better outcome and inferior mortality. Real-life data in a heterogeneous cohort are few. The aim of this study is to evaluate the benefit of prophylaxis with tixagevimab-cilgavimab in a cohort of 202 patients affected by different hematological diseases (lymphoproliferative, myeloproliferative, autoimmune, patients recently receiving a bone marrow transplant), active (with ongoing treatment), or in watch-and-wait strategy, followed in our center, during a median follow-up of 249 (45-325) days. An incidence of 44 breakthrough infections (21.8%) is reported, with no treatment-related adverse effects. Age ≥70 years, ongoing treatment (above all with monoclonal antibodies), baseline lymphoproliferative disorders, and prior virus exposure are identified as risk factors related to subsequent infection (p < 0.05). Moreover, the incidence is higher in low/nonresponse to prior vaccination (p = .002). Patients treated with tixagevimab-cilgavimab had a mild course of the infection and a reduction of the duration compared with preprophylaxis infection (11 vs. 15 days, p < .001). The concurrent treatment with anti-CD20 monoclonal antibodies and B-non-Hodgkin lymphoma still confers a higher duration of infection despite prophylaxis. No deaths attributable to the infection occurred. Prophylaxis treatment seems to be a valid and safe strategy, although not preventing breakthrough infection, but the severe complications associated with the infection and the possible delays in administering lifesaving therapies from long positivity.
Sections du résumé
BACKGROUND
BACKGROUND
Managing SARS-CoV-2 infection in frail and immunosuppressed patients still represents an open challenge, but, starting from the phase 3 PROVENT study, prophylaxis with tixagevimab-cilgavimab has improved the approach in this category of patients, guaranteeing a better outcome and inferior mortality. Real-life data in a heterogeneous cohort are few.
METHODS
METHODS
The aim of this study is to evaluate the benefit of prophylaxis with tixagevimab-cilgavimab in a cohort of 202 patients affected by different hematological diseases (lymphoproliferative, myeloproliferative, autoimmune, patients recently receiving a bone marrow transplant), active (with ongoing treatment), or in watch-and-wait strategy, followed in our center, during a median follow-up of 249 (45-325) days.
RESULTS
RESULTS
An incidence of 44 breakthrough infections (21.8%) is reported, with no treatment-related adverse effects. Age ≥70 years, ongoing treatment (above all with monoclonal antibodies), baseline lymphoproliferative disorders, and prior virus exposure are identified as risk factors related to subsequent infection (p < 0.05). Moreover, the incidence is higher in low/nonresponse to prior vaccination (p = .002). Patients treated with tixagevimab-cilgavimab had a mild course of the infection and a reduction of the duration compared with preprophylaxis infection (11 vs. 15 days, p < .001). The concurrent treatment with anti-CD20 monoclonal antibodies and B-non-Hodgkin lymphoma still confers a higher duration of infection despite prophylaxis. No deaths attributable to the infection occurred.
CONCLUSION
CONCLUSIONS
Prophylaxis treatment seems to be a valid and safe strategy, although not preventing breakthrough infection, but the severe complications associated with the infection and the possible delays in administering lifesaving therapies from long positivity.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 American Cancer Society.
Références
Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):1-15. doi:10.1186/S13045-021-01177-0/TABLES/5
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMOA2034577/SUPPL_FILE/NEJMOA2034577_PROTOCOL.PDF
Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407-1416. doi:10.1016/S0140-6736(21)02183-8
Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393-1400. doi:10.1056/NEJMOA2114255/SUPPL_FILE/NEJMOA2114255_DISCLOSURES.PDF
Palumbo GA, Cambria D, La Spina E, et al. Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine. Front Oncol. 2023;13:518. doi:10.3389/FONC.2023.1117815/BIBTEX
Duminuco A, Romano A, Leotta D, et al. Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab. Front Oncol. 2023;13:1357. doi:10.3389/FONC.2023.1157610/BIBTEX
Passamonti F, Romano A, Salvini M, et al. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. Br J Haematol. 2021;195(3):371-377. doi:10.1111/BJH.17704
Pagano L, Salmanton-García J, Marchesi F, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood;140(26), 2022:2773-2787. doi:10.1182/BLOOD.2022017257/1922289/BLOOD.2022017257
Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med386(23). 2022:2188-2200. doi:10.1056/NEJMOA2116620/SUPPL_FILE/NEJMOA2116620_DATA-SHARING
Scarfò L, Cuneo A. COVID-19 prophylaxis: half-full or half-empty glass? Blood. 2023;141(2):130-132. doi:10.1182/BLOOD.2022018858
Davis JA, Granger K, Roubal K, et al. Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies. Blood. 2023;141(2):200-203. doi:10.1182/BLOOD.2022018283
Abani O, Abbas A, Abbas F, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399(10325):665-676. doi:10.1016/S0140-6736(22)00163-5
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813-1826. doi:10.1056/NEJMOA2007764
Regalado-Artamendi I, Jiménez-Ubieto A, Hernández-Rivas JÁ, et al. Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study. Hemasphere. 2021;5(3):1-8. doi:10.1097/HS9.0000000000000538
Martín-Moro F, Marquet J, Piris M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020;190(1):e16. doi:10.1111/BJH.16801
Susek KH, Gran C, Ljunggren HG, Alici E, Nahi H. Outcome of COVID-19 in multiple myeloma patients in relation to treatment. Eur J Haematol. 2020;105(6):751-754. doi:10.1111/EJH.13502
Wang Z, Zhao Y, Wang Q, et al. Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 Mpro. Signal Transduct Targeted Ther. 2021;6(1):1-4. doi:10.1038/s41392-021-00639-8
Han MLK, Antila M, Ficker JH, et al. Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Rheumatol. 2022;4(5):e351-e361. doi:10.1016/S2665-9913(22)00044-3
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med;384(5); 2021:403-416. doi:10.1056/NEJMOA2035389/SUPPL_FILE/NEJMOA2035389_DATA-SHARING
Gallais F, Gantner P, Bruel T, et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine. 2021;71:71. doi:10.1016/j.ebiom.2021.103561
Petersen LR, Sami S, Vuong N, et al. Lack of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a large cohort of previously infected persons. Clin Infect Dis. 2021;73(9):e3066-e3073. doi:10.1093/CID/CIAA1685
Holmer HK, Mackey K, Fiordalisi CV, et al. Antibody response following SARS-CoV-2 infection and implications for immunity: final update of a rapid, living review. Published online October 28. doi:10.23970/AHRQEPCCOVIDIMMUNITY3
Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of immune response during SARS-CoV-2 infection: lessons from the past. Front Immunol. 2020;11:1949. doi:10.3389/FIMMU.2020.01949/BIBTEX
Angotzi F, Petrella M, Berno T, et al. Tixagevimab/cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies. Front Oncol. 2023;13:1212752. doi:10.3389/FONC.2023.1212752/BIBTEX
Justin Laracy by C, Yan J, Steiger SN, et al. Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients. Haematologica. 2020. doi:10.3324/HAEMATOL.2023.283015
SARS-CoV-2 variants of concern as of 4 May 2023. Accessed May 12, 2023. https://www.ecdc.europa.eu/en/covid-19/variants-concern